Debulking procedures not beneficial in patients with end-stage prostate cancer

The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

Concomitant abiraterone or enzalutamide did not boost the radium-223 survival benefit in patients with bone-dominant metastatic castration-resistant prostate cancer.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

No dose-limiting toxicities were observed among the initial 3 patients in cohort 3, and no patients experienced adverse events related to 64Cu-SAR-bisPSMA.

"However, these patients have an overall poor prognosis,” noted Mohamed E. Ahmed, MD.